South Africa Live Biotherapeutic Products And Microbiome Cdmo Market Size & Outlook
Related Markets
South Africa live biotherapeutic products and microbiome cdmo market highlights
- The South Africa live biotherapeutic products and microbiome cdmo market generated a revenue of USD 128.7 million in 2024 and is expected to reach USD 1,011.3 million by 2030.
- The South Africa market is expected to grow at a CAGR of 37.4% from 2025 to 2030.
- In terms of segment, c.difficle was the largest revenue generating application in 2024.
- C.difficle is the most lucrative application segment registering the fastest growth during the forecast period.
Live biotherapeutic products and microbiome cdmo market data book summary
| Market revenue in 2024 | USD 128.7 million |
| Market revenue in 2030 | USD 1,011.3 million |
| Growth rate | 37.4% (CAGR from 2025 to 2030) |
| Largest segment | C.difficle |
| Fastest growing segment | C.difficle |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | C.difficle, Crohns disease, IBS, Diabetes |
| Key market players worldwide | Carbios SA, Boise Cascade Co, Assembly Biosciences Inc, Wacker Chemie AG, SGS AG, Lonza Group Ltd, Arranta Bio, 4D Pharma, NIZO, Inpac Pharma |
Other key industry trends
- In terms of revenue, South Africa accounted for 0.2% of the global live biotherapeutic products and microbiome cdmo market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, South Africa live biotherapeutic products and microbiome cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Saudi Arabia is the fastest growing regional market in Middle East & Africa and is projected to reach USD 671.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Live Biotherapeutic Products And Microbiome CDMO Market Scope
Live Biotherapeutic Products And Microbiome CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Inpac Pharma | View profile | 51-100 | Lund, Skane Lan, Sweden, Europe | http://www.inpac.se |
| NIZO | View profile | 51-100 | Ede, Gelderland, The Netherlands, Europe | http://www.nizo.com |
| 4D Pharma | View profile | 101-250 | Aberdeen, Aberdeen City, United Kingdom, Europe | https://www.4dpharmaplc.com |
| Arranta Bio | View profile | 51-100 | Watertown, Massachusetts, United States, North America | http://arrantabio.com/ |
| Assembly Biosciences Inc | View profile | 65 | Two Tower Place, 7th Floor, South San Francisco, CA, United States, 94080 | https://www.assemblybio.com |
| Boise Cascade Co | View profile | 7310 | 1111 West Jefferson Street, Suite 300, Boise, ID, United States, 83702-5389 | https://www.bc.com |
| SGS AG | View profile | 103193 | 1 Place des Alpes, P.O. Box 2152, Geneva, Switzerland, CH-1211 | https://www.sgs.com |
| Carbios SA | View profile | 95 | 5, Rue de la Baume, Paris, France, 75008 | http://www.carbios.fr |
| Wacker Chemie AG | View profile | 16378 | Hanns-Seidel-Platz 4, Munich, BY, Germany, 81737 | https://www.wacker.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
South Africa live biotherapeutic products and microbiome cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to live biotherapeutic products and microbiome cdmo market will help companies and investors design strategic landscapes.
C.difficle was the largest segment with a revenue share of 138.31% in 2024. Horizon Databook has segmented the South Africa live biotherapeutic products and microbiome cdmo market based on c.difficle, crohns disease, ibs, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
South Africa is considered to be the largest market for pharmaceuticals in the sub-Saharan African region. It has one of the most developed infrastructures and the presence of a significant number of life sciences companies.
The market is expected to witness growth owing to a diverse population, the presence of well-established infrastructure, and the availability of experts. Clinical trials are outsourced to South Africa due to the easy availability of subjects for CDIs, which is the most common healthcareassociated enteric infection. Thus, growing clinical research outsourcing and increasing demand for drug development & research in the region are expected to boost market growth.
Reasons to subscribe to South Africa live biotherapeutic products and microbiome cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of South Africa live biotherapeutic products and microbiome cdmo market databook
-
Our clientele includes a mix of live biotherapeutic products and microbiome cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa live biotherapeutic products and microbiome cdmo market , including forecasts for subscribers. This country databook contains high-level insights into South Africa live biotherapeutic products and microbiome cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
South Africa live biotherapeutic products and microbiome cdmo market size, by application, 2018-2030 (US$M)
South Africa Live Biotherapeutic Products And Microbiome CDMO Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
